Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegeneration and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FBXO7 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FBXO7 Recombinant Protein (Full Length / Active Domains) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View FBXO7 Products |
| Gene Delivery | FBXO7 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View FBXO7 Products |
| Benchmark Ab | Anti-FBXO7 Recombinant Antibody Recombinant positive control for validation. |
View FBXO7 Products |
| Validator | FBXO7 siRNA Set For knockdown verification in functional assays. |
View FBXO7 Products |
| Related Target A | PINK1 Interacts with FBXO7 to facilitate mitophagy; critical in Parkinson's disease pathways. |
View PINK1 Products |
| Related Target B | Parkin Collaborates with FBXO7 and PINK1 in mitochondrial quality control. |
View Parkin Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting Active E3 Complex | Human recombinant FBXO7, SKP1, and CUL1 proteins strictly verified by mass spectrometry for stoichiometric assembly. |
| Screening Parkinson's Mutants | Sequence-verified FBXO7 mutant proteins (e.g., T22M, R378G) available for comparative binding and stability assays. |
| Lack of Controls | High-affinity recombinant anti-FBXO7 antibodies available as positive benchmark controls. |
| False Positives in Knockdown | Sequence-specific siRNA sets included to confirm phenotypic specificity of small molecule inhibitors. |
Live FBXO7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FBXO7 therapeutics is intensifying, with major players shifting focus from traditional target inhibition to targeted protein degradation (PROTACs/molecular glues) and gene therapy rescue. As first-generation therapies targeting the ubiquitin-proteasome system reach the clinic, the next wave of R&D is targeting FBXO7's dual role in mitochondrial maintenance (mitophagy) and cell cycle regulation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Molecular Glue | Biotech Startups, Academic Labs | Oncology (Cyclin D/CDK6 driven cancers) | Ternary complex formation assay (Requires high-purity FBXO7 and substrate proteins) |
| Gene Therapy (AAV/Lentivirus) | Neurodegenerative Disease Biopharma | Parkinson's Disease (PARK15) | Functional rescue assays (Requires Lentivirus for stable cell line generation) |
| Small Molecule Inhibitors | Oncology-focused Biotechs | Solid Tumors, Hematological Malignancies | High-throughput screening (Requires active recombinant FBXO7 and E3 complex components) |